Sale!

Cancer Targeted Gene Panel Lung with PDL-1 DAKO Test

5,400 د.إ

-25%

The “Cancer Targeted Gene Panel Lung with PDL-1 DAKO Test” is a sophisticated diagnostic procedure offered by DNA Labs UAE, aimed at providing a comprehensive genetic analysis for individuals with lung cancer. This test is designed to identify specific genetic mutations and alterations in lung cancer cells, which can significantly influence treatment decisions and outcomes. By examining a panel of genes associated with lung cancer, the test helps in identifying the most effective targeted therapies for each patient, thereby personalizing treatment plans.

Additionally, the test includes the PDL-1 DAKO test, which measures the expression of the PD-L1 protein in tumor cells. PD-L1 expression is a critical factor in determining the suitability of immunotherapy, particularly with checkpoint inhibitors. This aspect of the test is vital for patients with non-small cell lung cancer (NSCLC), as it helps in identifying those who are likely to benefit from immunotherapies targeting the PD-1/PD-L1 pathway.

Conducted at DNA Labs UAE, a facility known for its advanced diagnostic technologies and expertise in genetic testing, the “Cancer Targeted Gene Panel Lung with PDL-1 DAKO Test” is priced at 5400 AED. This cost reflects the comprehensive nature of the test, encompassing both the targeted gene panel and the PD-L1 expression analysis, offering valuable insights that can guide the management and treatment of lung cancer in a personalized manner.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Cancer Targeted Gene Panel Lung with PD-L1 (DAKO) Test

At DNA Labs UAE, we offer the Cancer Targeted Gene Panel Lung with PD-L1 (DAKO) Test. This molecular diagnostic test is designed to identify genetic mutations and alterations in lung cancer cells. By targeting specific genes involved in lung cancer development and the PD-L1 protein, this test provides valuable information for personalized treatment planning.

Test Components

  • ALK1
  • ROS1
  • MET amplification
  • MET mutation
  • KRAS
  • BRAF
  • ERBB2
  • EGFR
  • PDL-1 (Dako)

Price

AED 5400.0

Sample Condition

Submit a formalin-fixed paraffin-embedded tissue block. Ship at room temperature. Provide a copy of the Histopathology report, site of biopsy, and clinical history. A duly filled NGS Test Requisition Form is mandatory.

Report Delivery

Sample by 1st/16th of every month; Report 15th/30th of the same month

Method

IHC, FISH, NGS

Test Type

Cancer

Doctor

Oncologist

Test Department

Molecular Diagnostics

Pre Test Information

Provide a copy of the Histopathology report, site of biopsy, and clinical history. A duly filled NGS Test Requisition Form is mandatory.

Test Details

The Cancer Targeted Gene Panel: Lung with PD-L1 (DAKO) test is a molecular diagnostic test used to identify genetic mutations and alterations in lung cancer cells. This test specifically targets genes that are known to be involved in lung cancer development and progression, as well as the PD-L1 protein, which is a key target for immunotherapy treatments.

The test is performed on a sample of lung cancer tissue obtained through biopsy or surgery. The tissue is analyzed using advanced genomic sequencing technologies to identify specific mutations and alterations in the DNA of cancer cells.

The results of the test can help guide treatment decisions, as certain mutations may be targeted by specific therapies or immunotherapies. The PD-L1 protein is also analyzed as part of this test, as it is an important biomarker for predicting response to immunotherapy. PD-L1 is expressed on the surface of cancer cells and interacts with immune cells to suppress the immune response. Immunotherapy drugs such as checkpoint inhibitors target the PD-L1 protein to help activate the immune system and attack cancer cells.

Overall, the Cancer Targeted Gene Panel: Lung with PD-L1 (DAKO) test is a valuable tool for personalized treatment planning for patients with lung cancer, as it provides important information about the genetic makeup of their cancer cells and their potential response to specific therapies.

Test Name CANCER TARGETED GENE PANEL LUNG WITH PDL-1 DAKO Test
Components *ALK1 *ROS1 *MET amplification *MET mutation *KRAS *BRAF *ERBB2 *EGFR *PDL-1 (Dako)
Price 5400.0 AED
Sample Condition Submit Formalin fixed paraffin embedded tissue block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history. Duly filled NGS Test Requisition Formis mandatory.
Report Delivery Sample by 1st/16th of every month; Report 15th/30th of same month
Method IHC, FISH, NGS
Test type Cancer
Doctor Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Provide a copy of the Histopathology report, Site of biopsy and Clinical history. Duly filled NGS Test Requisition Formis mandatory.
Test Details

The Cancer Targeted Gene Panel: Lung with PD-L1 (DAKO) test is a molecular diagnostic test used to identify genetic mutations and alterations in lung cancer cells. This test specifically targets genes that are known to be involved in lung cancer development and progression, as well as the PD-L1 protein, which is a key target for immunotherapy treatments.

The test is performed on a sample of lung cancer tissue obtained through biopsy or surgery. The tissue is analyzed using advanced genomic sequencing technologies to identify specific mutations and alterations in the DNA of cancer cells. The results of the test can help guide treatment decisions, as certain mutations may be targeted by specific therapies or immunotherapies.

The PD-L1 protein is also analyzed as part of this test, as it is an important biomarker for predicting response to immunotherapy. PD-L1 is expressed on the surface of cancer cells and interacts with immune cells to suppress the immune response. Immunotherapy drugs such as checkpoint inhibitors target the PD-L1 protein to help activate the immune system and attack cancer cells.

Overall, the Cancer Targeted Gene Panel: Lung with PD-L1 (DAKO) test is a valuable tool for personalized treatment planning for patients with lung cancer, as it provides important information about the genetic makeup of their cancer cells and their potential response to specific therapies.